手机扫码接着看

moneyclickerscratch| A quick look at Boeing's (BA.US) rating today, with a high of US$270

Author:editor|Category:Parenting

May 24, US Eastern TimemoneyclickerscratchSeveral major Wall Street firms have updated their $Boeing (BAmoneyclickerscratch.US)$rating with target prices ranging from $147 to $270.

Barclays Bank analyst David E. Strauss maintains its hold rating and maintains its target price of $190.

moneyclickerscratch| A quick look at Boeing's (BA.US) rating today, with a high of US0

Furui Group analyst Sheila Kahyaoglu maintains a buy rating and maintains a target price of US$270.

Stiff analyst Bert Subin maintains a buy rating and lowered its target price to $230 from $240.

CFRA analyst Stewart Glickman maintained a sell rating and lowered his price target to $147 from $151.

Wolf Research analyst Myles Walton maintained a buy rating and lowered its target price to $220 from $260.

The following are the latest investment ratings and target price for $Boeing (BA.US)$by five analysts today:

Tips:

TipRanks is an independent third party that provides analytical data from financial analysts and calculates the average rate of return and winning percentage recommended by the analysts. The information provided is not investment advice and is for reference only. This document does not endorse, represent or warrant the completeness or accuracy of rating data and reports.

TipRanks provides each analyst's star rating. The analyst star rating represents all the analyst's recommended past performance. Through a comprehensive calculation of the analyst's total winning rate and average return rate, the more stars there are, the better the analyst's past performance, with a maximum of 5 stars.

The total analyst win rate is the ratio of the number of rating successes by analysts to the total number of ratings in the past year. The success of the rating depends on whether TipRanks 'virtual portfolio generates positive returns from the stock.

The total average rate of return is the rate of return obtained by a virtual portfolio created based on the analyst's initial rating and adjusted for rating changes in the past year.

24 05

2024-05-24 21:53:50

浏览9
Back to
Category
Back to
Homepage
slotostarscasino| Shanghai Pharmaceutical: I040 drug approved for clinical trials, opening a new chapter in new drug research and development livebettingroulette| Tiangong International (00826) spent HK$49,000 to repurchase 28,000 shares on May 24